Nura Bio

Private

#Amyotrophic lateral sclerosis (ALS)#Multiple sclerosis #Peripheral neuropathy

Clinical-stage neuroscience company developing SARM1 inhibitors for neurodegeneration including ALS and multiple sclerosis.

Company Info

Sector:Small Molecule Pharma

Headquarters:San Diego, California, USA

Founded:2018

Website:nurabio.com/

Funding Round:Series A

Total Funding:$73.8M (latest round, total undisclosed)

Funding & Investor Relations

Notable Investors

Undisclosed venture investors

Upcoming Milestones & Key Dates

2027 H1

Regulatory filing

IND filing for NB-100 in ALS

2026 H2

Financing event

Series B financing

Clinical Development Pipeline

NB-100

Target: SARM1 inhibitor

ALS

Preclinical

Phase 1

Phase 2

Phase 3

Approved

NB-200

Target: SARM1 inhibitor

Multiple sclerosis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

NB-300

Target: SARM1 inhibitor

Peripheral neuropathy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Nura Bio raises $73.8M to advance SARM1 inhibitors for neurodegeneration ↗

Nura Bio closes a $73.8M financing round to advance its SARM1 inhibitor pipeline for ALS and other neurodegenerative diseases.

Leadership Team

Shilpa Sambashivan, Ph.D.

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →